Vaccine innovation through MIPS and GSK collaboration

Vaccine innovation through MIPS and GSK collaboration

17 December 2015

GSK Australia today opened a new pilot vaccine facility at its Boronia site to manufacture a vaccine testing a new production method developed in collaboration with Monash University

If successful, it is hoped the new method could help to reduce overall vaccination costs which could help more children in developing countries access potentially life saving vaccines.

The GSK team in Boronia, working in partnership with Monash University and global vaccine experts in Belgium, has developed a ground-breaking way to use blow-fill-seal (BFS) to manufacture a vaccine.

At significant volumes, blow-fill-seal (BFS) technology is an efficient, cost effective way to manufacture high quality, sterile products. In a single process, BFS technology forms the container, fills it with the sterile liquid then seals the container to maintain a high assurance of sterility. No other technology does this with such a small production footprint and without the need for a supply chain of aseptic components.

Associated Professor David Morton said, "it's wonderful for Monash to be part of this innovation. Thanks to the GSK team our students and staff have had unique exposure to real-world challenges in advanced manufacturing and product development.  This industrial environment is where such true high-impact    Australian innovation thrives, and our future talent is created."